Analysts Set Oscar Health, Inc. (NYSE:OSCR) Price Target at $20.08

Oscar Health, Inc. (NYSE:OSCR) has received an average rating of “Hold” from the seven brokerages that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, two have given a hold recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $20.08.

Separately, Wells Fargo & Company cut Oscar Health from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $20.00 to $16.00 in a research report on Thursday, March 13th.

Insider Buying and Selling

In related news, Director Elbert O. Jr. Robinson sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $16.43, for a total value of $410,750.00. Following the transaction, the director now directly owns 64,512 shares in the company, valued at approximately $1,059,932.16. This represents a 27.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 24.39% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Southeastern Asset Management Inc. TN grew its position in Oscar Health by 52.2% during the fourth quarter. Southeastern Asset Management Inc. TN now owns 3,131,084 shares of the company’s stock valued at $42,082,000 after acquiring an additional 1,073,359 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its position in Oscar Health by 37.8% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,741,306 shares of the company’s stock valued at $23,403,000 after acquiring an additional 477,634 shares during the last quarter. Man Group plc grew its position in Oscar Health by 344.8% during the fourth quarter. Man Group plc now owns 1,813,216 shares of the company’s stock valued at $24,370,000 after acquiring an additional 1,405,554 shares during the last quarter. Lingotto Investment Management LLP bought a new position in Oscar Health during the fourth quarter valued at approximately $2,543,000. Finally, GDS Wealth Management grew its position in Oscar Health by 1,545.3% during the fourth quarter. GDS Wealth Management now owns 345,817 shares of the company’s stock valued at $4,648,000 after acquiring an additional 324,798 shares during the last quarter. 75.70% of the stock is currently owned by institutional investors.

Oscar Health Price Performance

NYSE OSCR opened at $16.72 on Friday. The firm’s 50-day simple moving average is $13.51 and its two-hundred day simple moving average is $14.62. Oscar Health has a 52 week low of $11.20 and a 52 week high of $23.79. The company has a market cap of $4.19 billion, a PE ratio of -835.58 and a beta of 1.75. The company has a quick ratio of 0.73, a current ratio of 0.73 and a debt-to-equity ratio of 0.26.

Oscar Health (NYSE:OSCR) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.09. Oscar Health had a return on equity of 2.28% and a net margin of 0.28%. The firm had revenue of $3 billion for the quarter, compared to analysts’ expectations of $2.87 billion. During the same period in the prior year, the business posted $0.62 earnings per share. The company’s revenue was up 42.2% on a year-over-year basis. Research analysts predict that Oscar Health will post 0.69 earnings per share for the current year.

Oscar Health Company Profile

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.